Visterra will use the proceeds to advance its pipeline of antibodies that target infectious diseases, including initiating phase 1 clinical trials for VIS410, its lead antibody for the prevention and treatment of seasonal and pandemic influenza. The company was seeded with $5.24 million in 2009, garnering a $10.7 million valuation at the time.